2月25日，中国中免跌5.18%，截至发稿，报80.77元/股，成交22.72亿元，换手率1.42%，总市值1671.02 亿元。 天治新消费混合（350008）基金经理为梁莉。 截至发稿，梁莉累计任职时间4年318天，现任基金资产总规模8816.05万元，任职期间最佳基金回报 32.27%， 任职期间最差基金回报-63.18%。 声明：市场有风险，投资需谨慎。 本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本 文出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 责任编辑：小浪快报 从基金十大重仓股角度 数据显示，天治基金旗下1只基金重仓中国中免。天治新消费混合（350008）四季度持有股数9500股， 占基金净值比例为4.71%，位居第一大重仓股。根据测算，今日浮亏损失约4.19万元。 天治新消费混合（350008）成立日期2011年8月4日，最新规模1907万。今年以来收益1.84%，同类排名 6560/8889；近一年亏损1.38%，同类排名7957/8136；成立以来亏损21.31%。 资料显示，中国旅游集团 ...

Core Insights - The article highlights the significant performance disparity among public funds over the past decade, with some achieving returns exceeding 580% while others have lost over 55% [2][3] - The leading funds are primarily focused on technology and consumer sectors, while underperforming funds are heavily invested in traditional industries [2][6] - The importance of selecting the right funds is emphasized, as the difference in returns can exceed 600 percentage points for long-term investors [2] Performance Overview - As of October 14, 2023, 601 funds have achieved returns over 100% in the last ten years, with 42 funds exceeding 300% [3] - The top-performing fund, Huashang New Trend Preferred, has a return rate of 586.49%, followed by Huashang Advantage Industry A at 488.74% and Guotai Nasdaq 100 ETF at 487.37% [4][6] - Funds focused on technology and emerging industries, such as Dongwu Mobile Internet A and Xin'ao New Energy Industry A, have also shown strong performance, with returns exceeding 350% [6][7] Underperforming Funds - A total of 76 funds have recorded cumulative losses over the past decade, with 32 funds having returns below 20% [8] - The worst-performing fund, Tianzhi New Consumption, has a loss of 53.03%, while others like Fangzheng Fubon Innovation Power A and Morgan Consumption Pioneer have also seen significant declines [9][12] - Many underperforming funds are linked to sectors such as real estate, media, and traditional manufacturing, indicating a failure to adapt to structural market changes [12]

中国经济网北京5月27日讯 智通财经于5月20日发布《名单炸裂？64位基金经理近三年跑输基准超 10%，还有百亿老将在列》称，据济安金信统计，截至今年4月30日，市场上有64位基金经理旗下全部 基金的近三年年化收益率均跑输基准超10%（各类份额合并计算，且仅统计成立满三年的产品）。 在上文所列举的旗下全部基金近三年年化收益率全部跑输基准超10%的基金经理名单中，天治基金管理 有限公司旗下基金经理梁莉在列。梁莉目前共管理着4只基金（各类份额分开计算），其中有3只基金的 管理时长超过3年，这3只基金近三年年化收益率均跑输基准超10%。 上述3只基金的规模均偏小，截至2025年一季度末，天治趋势精选混合、天治新消费混合、天治中国制 造2025的规模分别为0.05亿元、0.17亿元、0.14亿元。 其中，梁莉管理时长最久的是天治中国制造2025，累计超过4年，但任职回报仅为-36.87%。该基金近1 年、近2年、近3年收益率分别为-5.79%、-29.28%、-32.73%，同期沪深300指数涨幅分别为7.18%、 0.24%、-3.33%。截至今年一季度末，该基金的前十大重仓股分别为恒润股份（603985）、安凯客 ...

Core Viewpoint - The China Securities Regulatory Commission has released an action plan to promote high-quality development of public funds, emphasizing the importance of performance benchmarks and their impact on fund managers' evaluations and compensation [2][8]. Group 1: Fund Performance and Benchmarking - The action plan requires fund performance deviations from benchmarks to be included in the evaluation and reward systems for fund companies and managers [2]. - Three funds, namely the Jiashi Intelligent Automotive Stock Fund, Jinying Multi-Strategy Mixed A Fund, and Tianzhi New Consumption Mixed Fund, have underperformed their benchmarks by over 60 percentage points in the past three years, highlighting significant deviations [2][6][7]. - Jiashi Intelligent Automotive Stock Fund has underperformed its benchmark by 81.83 percentage points, primarily due to a misalignment in investment strategy focusing heavily on upstream lithium battery materials while neglecting downstream automotive sectors [3][4]. Group 2: Fund Manager Strategies and Changes - The Jiashi Intelligent Automotive Fund's manager has maintained a concentrated position in lithium battery stocks despite market shifts towards vehicle intelligence and optimization, resulting in significant losses [3][4]. - The Jinying Multi-Strategy Mixed A Fund has changed managers six times in nine years, leading to inconsistent investment strategies and a 71.14 percentage point underperformance against its benchmark [6]. - The Tianzhi New Consumption Mixed Fund has struggled with a heavy allocation in the pig farming sector amid a slow consumer recovery, resulting in a 61.45 percentage point underperformance [7]. Group 3: Regulatory Impact and Industry Trends - The new regulatory framework aims to enhance the stability and consistency of fund investment strategies by linking fund manager compensation to performance benchmarks [8]. - The emphasis on performance benchmarks is expected to lead to a more transparent investment environment, reducing the difficulty for investors in selecting funds and increasing trust in public funds [8]. - The industry may see a shift towards more conservative investment styles as fund managers align their strategies with mainstream broad-based indices [8].

Group 1 - Rongchang Biologics (688331.SH) released its 2024 annual report on March 28, 2025, indicating that as of March 27, 2025, 29 institutional investors disclosed holding a total of 214 million shares, accounting for 39.31% of the total share capital [1] - The top ten institutional investors include Yantai Rongda Venture Capital Center (Limited Partnership), Yantai Rongqian Enterprise Management Center (Limited Partnership), and others, with a combined holding ratio of 36.29%, showing a slight decrease of 0.04 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, two funds increased their holdings, including Huatai-PineBridge Medical Service Flexible Allocation Mixed A and Huatai-PineBridge Daxin Mixed A, with an increase ratio of 0.38% [2] - Two public funds reduced their holdings, including Bank of China Innovation Medical Mixed A and Rongtong Vision Value One-Year Holding Period Mixed A, showing a slight decline [2] - Three new public funds were disclosed this period, including China Merchants National Index Biomedicine A, Tianzhi New Consumption Mixed, and Zhongtai CSI 500 Index Enhanced A [2] - Twenty-one public funds were not disclosed this period, including E Fund Healthcare Industry Mixed A and Bank of China Healthcare Mixed A [2]